Sedana Medical Q3: Initial take - Redeye

Redeye provides its initial comment on Sedana Medical’s Q3 report. Sales came in 10% below our forecast, but good cost control demonstrates the company’s ability to continue growing whilst overlooking its OPEX. We will shortly return with a more detailed take on the report in a coming update.

Länk till analysen i sin helhet: https://www.redeye.se/research/950622/sedana-medical-q3-initial-take?utm_source=finwire&utm_medium=RSS